<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126004</url>
  </required_header>
  <id_info>
    <org_study_id>SOOCHOW-HY-2021-2</org_study_id>
    <nct_id>NCT05126004</nct_id>
  </id_info>
  <brief_title>AZA Combined With NAC for PIT After HSCT</brief_title>
  <official_title>Azacitidine (AZA) Combined With N-Acetyl-L-cysteine (NAC) for Prolonged Isolated Thrombocytopenia (PIT) After Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has&#xD;
      remained a critical complication after allogeneic hematopoietic cell transplantation since&#xD;
      decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical&#xD;
      practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential&#xD;
      in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition,&#xD;
      decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT&#xD;
      in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT&#xD;
      was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC)&#xD;
      was the most commonly used antioxidant. Therefore, the investigators have been wondering&#xD;
      whether Azacitidine in combination with NAC could improve PIT post HSCT and explore the&#xD;
      possible mechanism of it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has&#xD;
      remained a critical complication after allogeneic hematopoietic cell transplantation since&#xD;
      decades years ago. Recombinant human thrombopoietin (rhTPO) is the main therapy in clinical&#xD;
      practice, but remains low efficiency for PIT. Demethylating drugs have shown thier potential&#xD;
      in high-risk myelodysplastic syndromes (MDS) and acte myeloid leukemia (AML). In addition,&#xD;
      decitabine has demonstrated its efficacy of over 70% for response rate in treatment for PIT&#xD;
      in early clinical trials with elusive mechanism. Preliminary experiments revealed that PIT&#xD;
      was associated with abnormality of oxidation microenvironment, and N-Acetyl-L-cysteine (NAC)&#xD;
      was the most commonly used antioxidant. Furthermore, AZA had shown its potential in immune&#xD;
      regulation. Therefore, the investigators have been wondering whether Azacitidine in&#xD;
      combination with NAC could improve PIT post HSCT and explore the possible mechanism of it.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Arm1: Control Arm2:AZA+NAC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>platelet reconstruction</measure>
    <time_frame>From date of randomization until the date of platelet reconstruction, assessed up to 100 days</time_frame>
    <description>platelet count above 50*10^9/L independent of transfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 1 year</time_frame>
    <description>the time from the date of day 1 post HSCT to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>From date of randomization until the date of platelet count between 30*10^9/L and 50*10^9/L, assessed up to 100 days</time_frame>
    <description>platelet count evaluating above 30*10^9/L but below 50*10^9/L independent of platelet transfusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>infection</measure>
    <time_frame>From date of randomization until the date of diagnose of infection, assessed up to 100 days</time_frame>
    <description>clinical diagnose of infection or evidence of next generation of sequencing（NGS）of body fluid or CT or culture of samples collected from patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>From date of randomization until the date of occurrence of any severe adverse event, assessed up to 100 days</time_frame>
    <description>any events that prevent the clinical trial continue besides hepatic injury renal function impairment, et al.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thrombocytopenia, Isolated</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>receive supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZA+NAC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZA 50mg Subcutaneous daily d1-d5 + NAC 600mg oral bid d1-28， 28 days for one cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.</description>
    <arm_group_label>AZA+NAC group</arm_group_label>
    <other_name>AZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N Acetyl L Cysteine</intervention_name>
    <description>28 days for one cycle, evaluation post 3 cycles of treatment. Continue if response exists, otherwise, quit the trial and seek for other therapies.</description>
    <arm_group_label>AZA+NAC group</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Platelet count ≤ 30 × 10^9/L persistently at day 60 post-HSCT or later;&#xD;
&#xD;
          -  Neutrophil and hemoglobin were well recovered;&#xD;
&#xD;
          -  Full donor chimerism was achieved;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with malignancy relapse;&#xD;
&#xD;
          -  Active infections;&#xD;
&#xD;
          -  Grade Ⅲ-Ⅳ acute graft-versus-host disease or severe chronic graft-versus-host disease&#xD;
             according to National Institute of Health criteria;&#xD;
&#xD;
          -  Severe organ damage;&#xD;
&#xD;
          -  Thrombosis requiring treatment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yue Han, PhD,MD</last_name>
    <phone>0512-67781856</phone>
    <email>hanyue@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Depei Wu, PhD,MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first affiliated hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yue Han, PhD, MD</last_name>
      <phone>8615606133002</phone>
      <email>hanyue@suda.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Meng Zhou, MD</last_name>
      <phone>8615606133002</phone>
      <email>zhoumeng@suda.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>First LR, Smith BR, Lipton J, Nathan DG, Parkman R, Rappeport JM. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes. Blood. 1985 Feb;65(2):368-74.</citation>
    <PMID>3881142</PMID>
  </reference>
  <reference>
    <citation>Bruno B, Gooley T, Sullivan KM, Davis C, Bensinger WI, Storb R, Nash RA. Secondary failure of platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7(3):154-62.</citation>
    <PMID>11302549</PMID>
  </reference>
  <reference>
    <citation>Wang H, Huang M, Zhao Y, Qi JQ, Chen C, Tang YQ, Qiu HY, Fu CC, Tang XW, Wu DP, Ruan CG, Han Y. Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Oct;23(10):1678-1684. doi: 10.1016/j.bbmt.2017.06.010. Epub 2017 Jun 19.</citation>
    <PMID>28642072</PMID>
  </reference>
  <reference>
    <citation>Zhao X, Zhao X, Huo M, Fan Q, Pei X, Wang Y, Zhang X, Xu L, Huang X, Liu K, Chang Y. Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated Thrombocytopenia and Inferior Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation. J Immunol Res. 2017;2017:1043836. doi: 10.1155/2017/1043836. Epub 2017 Apr 16.</citation>
    <PMID>28484721</PMID>
  </reference>
  <reference>
    <citation>Ramírez P, Brunstein CG, Miller B, Defor T, Weisdorf D. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant. 2011 Jul;46(7):981-6. doi: 10.1038/bmt.2010.218. Epub 2010 Oct 4.</citation>
    <PMID>20921943</PMID>
  </reference>
  <reference>
    <citation>Tang Y, Chen J, Liu Q, Chu T, Pan T, Liang J, He XF, Chen F, Yang T, Ma X, Wu X, Hu S, Cao X, Hu X, Hu J, Liu Y, Qi J, Shen Y, Ruan C, Han Y, Wu D. Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial. Blood Adv. 2021 Mar 9;5(5):1250-1258. doi: 10.1182/bloodadvances.2020002790.</citation>
    <PMID>33646303</PMID>
  </reference>
  <reference>
    <citation>Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell. 2010 Aug 6;7(2):150-61. doi: 10.1016/j.stem.2010.07.007. Review.</citation>
    <PMID>20682444</PMID>
  </reference>
  <reference>
    <citation>Chen S, Su Y, Wang J. ROS-mediated platelet generation: a microenvironment-dependent manner for megakaryocyte proliferation, differentiation, and maturation. Cell Death Dis. 2013 Jul 11;4:e722. doi: 10.1038/cddis.2013.253. Review.</citation>
    <PMID>23846224</PMID>
  </reference>
  <reference>
    <citation>Kong Y, Shi MM, Zhang YY, Cao XN, Wang Y, Zhang XH, Xu LP, Huang XJ. N-acetyl-L-cysteine improves bone marrow endothelial progenitor cells in prolonged isolated thrombocytopenia patients post allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2018 Jul;93(7):931-942. doi: 10.1002/ajh.25056. Epub 2018 Feb 24.</citation>
    <PMID>29396859</PMID>
  </reference>
  <reference>
    <citation>Han Y, Tang Y, Chen J, Liang J, Ye C, Ruan C, Wu D. Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study. JAMA Oncol. 2015 May;1(2):249-51. doi: 10.1001/jamaoncol.2014.316.</citation>
    <PMID>26181032</PMID>
  </reference>
  <reference>
    <citation>Zhou H, Hou Y, Liu X, Qiu J, Feng Q, Wang Y, Zhang X, Min Y, Shao L, Liu X, Li G, Li L, Yang L, Xu S, Ni H, Peng J, Hou M. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia. Thromb Haemost. 2015 May;113(5):1021-34. doi: 10.1160/TH14-04-0342. Epub 2015 Jan 8.</citation>
    <PMID>25566808</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azacitidine</keyword>
  <keyword>N-Acetyl-L-cysteine</keyword>
  <keyword>Prolonged Isolated Thrombocytopenia</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 1, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT05126004/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

